Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated October 25, 2018, reports on an Extraordinary General Meeting of Shareholders convened by Cellect Biotechnology Ltd. (the "Company"). The filing documents the approval of corporate governance changes and executive compensation arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and equity compensation matters.
Material Changes
- Board Election: Jonathan Burgin was elected as an external director for a three-year term ending October 24, 2021.
- Committee Assignments: Mr. Burgin will serve on the Company's audit committee and compensation committee.
- Equity Grant: In connection with his election, Mr. Burgin was granted 150,000 options to purchase ordinary shares (represented by 7,500 ADSs).
Guidance, Outlook, and Compensation Details
The filing contains no financial guidance, outlook, or management commentary regarding operational performance. It details the terms of the option grant to Mr. Burgin:
- Exercise Price: NIS 0.899 per option.
- Vesting Schedule: Four-year period; 25% vests on October 24, 2019, with the balance vesting quarterly (6.25% per quarter).
- Acceleration: Vesting accelerates in the event of a change of control.
- Expiration: Options expire 10 years from the date of issuance.
Investor Verification Checklist
- Verify the impact of the new director's appointment on the composition of the audit and compensation committees.
- Review the Company's 2014 Global Incentive Option Scheme for terms not specified in this filing.
- Confirm the dilution effect of the 150,000 options granted to Mr. Burgin on existing shareholders.
- Check subsequent filings for any financial updates, as this document contains no financial data.